Biogen Inc. (FRA:IDP)
Germany
· Delayed Price · Currency is EUR | Market Cap | 22.86B |
| Revenue (ttm) | 8.58B |
| Net Income (ttm) | 1.37B |
| Shares Out | n/a |
| EPS (ttm) | 9.35 |
| PE Ratio | 16.68 |
| Forward PE | 13.86 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 50 |
| Average Volume | 188 |
| Open | 156.25 |
| Previous Close | 155.90 |
| Day's Range | 155.65 - 157.05 |
| 52-Week Range | 99.82 - 158.65 |
| Beta | n/a |
| RSI | 62.38 |
| Earnings Date | Feb 12, 2026 |
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r... [Read more]
Financial Performance
In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.
Financial numbers in USD Financial StatementsNews
BIIB January 2026 Options Begin Trading
Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the January 2026 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options...
Eisai And Biogen Report Long-Term Benefits Of LEQEMBI In Early Alzheimer's Disease
(RTTNews) - Eisai Co., Ltd. and Biogen Inc. announced new findings on the continued and expanding benefit of LEQEMBI (lecanemab-irmb) maintenance treatment in early Alzheimer's disease at the 18th Cli...
Biogen (BIIB) Reports Promising Lecanemab Findings for Alzheimer's Treatment
Biogen (BIIB) Reports Promising Lecanemab Findings for Alzheimer's Treatment
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025
Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer's disease by up to 8.3 years in low-amyloid group who started tre...
Biogen Inc. (BIIB) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Biogen Inc. (BIIB) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Biogen (BIIB) Sees Promising Lecanemab Results in Alzheimer's Treatment
Biogen (BIIB) Sees Promising Lecanemab Results in Alzheimer's Treatment
New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
TOKYO and CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massach...
New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
TOKYO and CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massach...
Biogen Inc. (BIIB) Presents at Evercore 8th Annual Healthcare Conference Transcript
Biogen Inc. (BIIB) Presents at Evercore 8th Annual Healthcare Conference Transcript
Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in patients with Dravet syndrome treated with zorevunersen support the potenti...
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R...
Biogen, Eisai File In Japan To Make Leqembi A Weekly At-Home Alzheimer's Shot
Biogen Inc. ‘s (NASDAQ: BIIB) partner Eisai Co., Ltd , on Friday filed a new drug application for Leqembi (lecanemab) seeking approval for a subcutaneous formulation (SC-AI) as a new route of adminis...
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer's Disease in Japan
If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the initiation of treatment for this progressive, relentless disease If approved, ...
Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline
BIIB's research deal with Dayra targets oral macrocyclic peptides to advance its immunology pipeline and expand next-generation therapies.
Biogen (BIIB) Advances Alzheimer's Treatment with FDA Submission
Biogen (BIIB) Advances Alzheimer's Treatment with FDA Submission
Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this ...
Eisai Completes Rolling Submission to US FDA for LEQEMBI IQLIK (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this ...
Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
TOKYO and CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ: BIIB , Corporate headquarters: Cambridge, Massac...
How Do Investors Really Feel About Biogen Inc?
Biogen Inc's (NYSE: BIIB) short interest as a percent of float has risen 8.75% since its last report. According to exchange reported data, there are now 5.64 million shares sold short , which is 4.97...
Why Is Biogen Stock Trading Higher After Semaglutide Alzheimer's Data?
Biogen Inc. (NASDAQ: BIIB) stock traded higher after Novo Nordisk A/S (NYSE: NVO) released disappointing topline results from the 2-year primary analysis of Evoke and Evoke+ phase 3 trials in early-st...
Why Is Biogen Stock Trading Higher After Semaglutide Alzheimer's Data?
Biogen Inc. (NASDAQ: BIIB) stock traded higher after Novo Nordisk A/S (NYSE: NVO) released disappointing topline results from the 2-year primary analysis of Evoke and Evoke+ phase 3 trials in early-...
Biogen (BIIB) Partners with Dayra Therapeutics to Develop Oral Macrocyclic Peptides
Biogen (BIIB) Partners with Dayra Therapeutics to Develop Oral Macrocyclic Peptides
Biogen, Dayra Therapeutics Partner To Develop Oral Macrocyclic Peptides For Immunological Diseases
(RTTNews) - Biogen Inc. (BIIB) said Monday that it has entered into a partnership with Dayra Therapeutics to discover and develop oral macrocyclic peptides for immunological conditions.
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
CAMBRIDGE, Mass. and TORONTO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Dayra Therapeutics today announced a research collaboration to discover and develop oral macrocyclic pept...
Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen Partnership
TORONTO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Versant Ventures today announced the launch of Dayra Therapeutics, a startup focused on developing oral macrocyclic peptides for a range of serious disease...